Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...
The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
It was determined that the capivasertib combination was unlikely to meet the 2 endpoints vs the comparator arm. AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap ™ (capivasertib). Truqap ™ is an ...
CHICAGO -- Adding investigational capivasertib to fulvestrant extended survival in patients with aromatase inhibitor-resistant estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, ...
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia Supported by the National Institute for Health Research and Cancer Research UK funding to the Barts ...
Credit: Getty Images. Capivasertib is a potential first-in-class AKT inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for capivasertib ...
USA, New York State, New York City Adding capivasertib to treatment with fulvestrant improved progression-free survival in aromatase inhibitor-resistant, HR+, HER2- advanced breast cancer. Adding ...
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled ...
Please provide your email address to receive an email when new articles are posted on . The results from the CAPItello-291 trial were presented at this year’s San Antonio Breast Cancer Symposium. She ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results